Tech Company Financing Transactions

Marrow Therapeutics Funding Round

On 11/17/2026, Marrow Therapeutics secured $173 million in financing from OrbiMed, venBio and Affinity Asset Advisors.

Transaction Overview

Announced On
11/17/2026
Transaction Type
Venture Equity
Amount
$173,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to advance its bone marrow-targeted genetic medicine programs toward the clinic and expand its manufacturing capabilities.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Forge Road 200
Watertown, MA 02472
USA
Phone
Undisclosed
Email Address
Overview
Marrow Therapeutics is developing precision medicines to transform the lives of people with sickle cell disease, beta thalassemia and other severe blood diseases. We specifically target the cells affected by these diseases early in their development using validated, antibody-based therapeutics with the potential to achieve a functional cure. Our expert team has deep experience developing tissue-targeted therapeutics and is committed to delivering transformational medicines for patients.
Profile
Marrow Therapeutics LinkedIn Company Profile
Social Media
Marrow Therapeutics Company Twitter Account
Company News
Marrow Therapeutics News
Facebook
Marrow Therapeutics on Facebook
YouTube
Marrow Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Romesh Subramanian
  Romesh Subramanian LinkedIn Profile  Romesh Subramanian Twitter Account  Romesh Subramanian News  Romesh Subramanian on Facebook
Chief Financial Officer
Joanne Bryce
  Joanne Bryce LinkedIn Profile  Joanne Bryce Twitter Account  Joanne Bryce News  Joanne Bryce on Facebook
Chief Operating Officer
John Najim
  John Najim LinkedIn Profile  John Najim Twitter Account  John Najim News  John Najim on Facebook
Chief Scientific Officer
Timothy Weeden
  Timothy Weeden LinkedIn Profile  Timothy Weeden Twitter Account  Timothy Weeden News  Timothy Weeden on Facebook
Founder
Gavriel Mullokandov
  Gavriel Mullokandov LinkedIn Profile  Gavriel Mullokandov Twitter Account  Gavriel Mullokandov News  Gavriel Mullokandov on Facebook
Vice President
Eleanor Lisbon
  Eleanor Lisbon LinkedIn Profile  Eleanor Lisbon Twitter Account  Eleanor Lisbon News  Eleanor Lisbon on Facebook
VP - Human Resources
Tamara McGrillen
  Tamara McGrillen LinkedIn Profile  Tamara McGrillen Twitter Account  Tamara McGrillen News  Tamara McGrillen on Facebook
VP - Operations
Colby Wolfe
  Colby Wolfe LinkedIn Profile  Colby Wolfe Twitter Account  Colby Wolfe News  Colby Wolfe on Facebook
VP - R & D
Kim Tang
  Kim Tang LinkedIn Profile  Kim Tang Twitter Account  Kim Tang News  Kim Tang on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/17/2026: Vucar venture capital transaction
Next: 11/17/2026: Bevado venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary